CONTACT
+91 80 2808 2808
info@biocon.com

News - Posts

Biocon  /  News – Posts

Biocon expands generic formulations portfolio with the launch of Tacrolimus capsules in the US

Biocon expands generic formulations portfolio with the launch of Tacrolimus capsules in the US
  • Posted by: BIOCON

Biocon Biologics Statement on the Status of Bevacizumab FDA Action Date in Dec 2020

  • Posted by: BIOCON

Biocon Biologics signs an MoU with CSSC in Tanzania for Mission 10 cents

Biocon Biologics signs an MoU with CSSC in Tanzania for Mission 10 cents
  • Posted by: BIOCON

Biocon Biologics and Mylan Receive CHMP Recommendation for Approval of Biosimilar Insulin Aspart

Biocon Biologics and Mylan Receive CHMP Recommendation for Approval of Biosimilar Insulin Aspart
  • Posted by: BIOCON

Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs

  • Posted by: BIOCON

Biocon Ranked Among Top 5 Biotech Employers Globally

  • Posted by: BIOCON

Biocon Q2FY21 Revenue at Rs 1,760 Cr, Up 10%; EBITDA at Rs 407 Cr; Net Profit (before exceptional item & discontinuing operations) at Rs 174 Cr; Generics Up 8% at Rs 599 Cr; Biosimilars Up 11% at Rs 676 Cr; Research Services Up 12% at Rs 520 Cr.

  • Posted by: BIOCON

Biocon Foundation Signs MoU with Bangalore Metro to Contribute Towards Building Metro Station in Hebbagodi

  • Posted by: BIOCON

Biocon Biologics to Roll Out ‘Mission 10 cents’ in Philippines; Signs MoU with 2 Municipal Governments & reach52 to enable Affordable Access to Quality Insulins

  • Posted by: BIOCON

Biocon appoints Anupam Jindal as its Chief Financial Officer

  • Posted by: BIOCON
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>